Authors
Latest:
Azacitidine Plus APR-246 Appears Promising as Treatment of TP53-Mutant MDS and AMLThomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Latest:
Patients Are Ready for Personalized Health Care, and the Data DeliversDevices like smart blood pressure cuffs, scales, and even smartphones with health sensors are turning our daily routines into personalized health insights.
Latest:
Advancements in Precision Radiation Treatment With the MR-LINACPaul B. Renz, DO, discusses anecdotal changes observed by clinician researchers using the MR-LINAC system.
Latest:
New Pathways for Oncolytic Virals in Breast CancerJohanna Kaufmann, PhD, discusses promising preclinical findings on first-in-class oncolytic viral therapy in breast cancer treatment.
Latest:
Future Directions in GVHDPashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.
Latest:
Best Practices and Strategies for Luspatercept in the Treatment of LR-MDSThomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of early and accurate diagnosis, considering newer therapies like luspatercept, monitoring hemoglobin levels, and incorporating patient-reported outcomes to tailor individualized treatment plans for better outcomes.
Latest:
Integrating Personalized Medicine: Advice for Medical OncologistsTracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.
Latest:
Treatment Failure in CML: Distinguishing Between Disease Resistance and Treatment IntolerancePatients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.
Latest:
Evaluating Current Challenges in Hepatocellular CarcinomaAnjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.
Latest:
Ever-Changing Treatment Landscape of Aggressive B-Cell LymphomaJason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Latest:
Revised Panobinostat Combination Shows Efficacy in Multiple MyelomaAndrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.
Latest:
Ide-Cel Shows Benefit for Multiple Myeloma After 2 to 4 Lines of TherapyAbdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Latest:
Evaluating the Impact of Genetic Mutations on Prostate Cancer Survival RatesRohan Garje, MD, provides an overview of a study evaluating how mutations, including TP53, RB1, and PTEN, impact overall survival in patients with metastatic prostate cancer.
Latest:
Outpatient Cilta-cel for Relapsed/Refractory Multiple MyelomaTaiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma.
Latest:
Cho Provides Background on the Multiple Myeloma Research Foundation’s CureCloud StudyHearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.
Latest:
Providing Resources for Relocation Expands CAR T Access in RRMMSamer A. Al’Hadidi, MD, discusses social determinants and resources that can help patients receive chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Latest:
Targeting PIK3CA Mutations in Breast CancerAndreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors.
Latest:
Breakthrough in TNBC Treatment: Avelumab Extends Overall SurvivalPierfranco Conte, MD, discusses findings and implications of the A-BRAVE study.
Latest:
Key Takeaways on Recent Data in Breast Cancer from SABCS 2023Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in breast cancer.
Latest:
Elacestrant Outperforms SOC in Terms of PFS in ER+/HER2– mBCPatients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.
Latest:
World Cancer Day: Next Generation Sequencing at the Forefront of Precision MedicineNext generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.
Latest:
Transforming Prostate Cancer Care Through Personalized MedicineAdam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Latest:
ASCO 2025: Highlights From TiNivo-2 TrialPanelists discuss how recent updates in progression free survival data complement secondary endpoints of overall survival, overall response rates, and duration of response to provide a comprehensive picture of treatment efficacy.
Latest:
Exploring Quality of Life in Bladder and Prostate Cancer at ASCO GU 2025Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers Symposium.
Latest:
Navigating Treatment Options for HER2+ BC: A Need for CustomizationAdrienne Waks, MD, discusses the unmet needs in early-stage HER2-positive breast cancer.
Latest:
Final ThoughtsPanelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.
Latest:
Telehealth Becomes Mainstream in Oncology PracticesDavid W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.
Latest:
Advice for Oncologists and Next Steps for the CLEAR Trial in RCCViktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
